Whether these mutations have a prognostic or predictive value remains elusive. Furthermore, the clinical relevance of the extended RAS (KRAS+NRAS) mutational status is unclear in PC. We ...

Erasca continues developing novel RAS-pathway cancer drugs, backed by funding through 2027 and promising early results. Find ...

These inhibitors use a different mechanism of action than most other KRAS inhibitors (including that in the previous study) ...

Credit: Canadian Light Source The researchers found that when the Ras protein is in its mutated, cancer-causing state, "molecules snuggle inside the pocket. Using crystallography, we were able to ...

as well as the potential expanded therapeutic index of ERAS-4001 through selective targeting of key KRAS mutations. We are excited to achieve our goal of advancing development of both RAS ...

as well as the potential expanded therapeutic index of ERAS-4001 through selective targeting of key KRAS mutations. We are excited to achieve our goal of advancing development of both RAS ...

Preclinical data demonstrates synergy of QTX3544 with EGFR inhibitors, broadly enhancing anti-tumor activity - - Data supports ongoing Phase 1 clinical trial for QTX3544 as monotherapy and in ...

Sustained reactivation of mutant p53 drives durable anti-tumor activity across models, including KRAS co-mutant tumorsFMC-220 selectively stabilizes p53 Y220C at lower doses, overcoming key ...

The RAS(ON) inhibitor shrunk tumors in around 60 percent of patients with KRAS G12D mutations, according to a study presented at AACR's annual meeting.

First-in-class examples of direct SHOC2 binders and modulators of SMP complex assembly identified with potential to block oncogenic RAS/MAPK pathway signaling SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE ...